The following IPOs are expected to price this week:
Argos Therapeutics (ARGS), which is developing immunotherapies for the treatment of cancer and HIV, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Argos Therapeutics would command a market value of $247 million. Argos Therapeutics, which was founded in 1997, booked $5 million in sales over the last 12 months. The Durham, NC-based company plans to list on the NASDAQ under the symbol ARGS. Piper Jaffray, Stifel and JMP Securities are the joint bookrunners on the deal.
Auspex Pharmaceuticals (ASPX), a clinical-stage biotech developing treatments for orphan diseases, plans to raise $61 million by offering 5.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Auspex Pharmaceuticals would command a market value of $231 million. Auspex Pharmaceuticals, which was founded in 2001, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol ASPX. Stifel and BMO Capital Markets are the joint bookrunners on the deal.
Biocept (BIOC), which develops and markets cancer diagnostic tests, plans to raise $20 million by offering 1.8 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Biocept would command a market value of $52 million. Biocept, which was founded in 1997, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol BIOC. Aegis Capital is the lead bookrunner on the deal.
Continental Building Products (CBPX), which manufactures and sells drywall in the eastern US and Canada, plans to raise $225 million by offering 13.2 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Continental Building Products would command a market value of $750 million. Continental Building Products, which was founded in 1996, booked $376 million in pro forma sales over the last 12 months. The Reston, VA-based company plans to list on the NYSE under the symbol CBPX. Citi, Credit Suisse, Barclays and Deutsche Bank are the joint bookrunners on the deal.
Egalet (EGLT), which is developing abuse-deterrent oral products for the treatment of pain, plans to raise $42 million by offering 3.5 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Egalet would command a market value of $167 million. Egalet, which was founded in 1995, booked $0 million in sales over the last 12 months. The Malvern, PA-based company plans to list on the NASDAQ under the symbol EGLT. Stifel and JMP Securities are the joint bookrunners on the deal.
Eleven Biotherapeutics (EBIO), a clinical-stage biotech developing protein therapeutics to treat dry eye diseases, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Eleven Biotherapeutics would command a market value of $206 million. Eleven Biotherapeutics, which was founded in 2008, booked $1 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol EBIO. Citi, Cowen & Company and Leerink Partners are the joint bookrunners on the deal.
Genocea Biosciences (GNCA), which develops novel vaccines for infectious diseases through T cell immune responses, plans to raise $72 million by offering 5.5 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Genocea Biosciences would command a market value of $224 million. Genocea Biosciences, which was founded in 2006, booked $1 million in sales over the last 12 months. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol GNCA. Citi, Cowen & Company and Stifel are the joint bookrunners on the deal.
GeoPark (GPRK), an oil and natural gas E&P operating in Chile, Colombia and Brazil, plans to raise $180 million by offering 20.0 million shares at a price range of $8.00 to $10.00. At the midpoint of the proposed range, GeoPark would command a market value of $575 million. GeoPark, which was founded in 2002, booked $319 million in sales over the last 12 months. The Santiago, Chile-based company plans to list on the NYSE under the symbol GPRK. J.P. Morgan, BTG Pactual and Itau BBA are the joint bookrunners on the deal. (Please note: Shares currently trade on the London Stock Exchange and the Santiago Offshore Stock Exchange under the ticker GPK.)
Ladder Capital (LADR), a commercial real estate mortgage origination and finance company, plans to raise $225 million by offering 13.3 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Ladder Capital would command a market value of $1.7 billion. Ladder Capital, which was founded in 2008, booked $322 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol LADR. Deutsche Bank, Citi, Wells Fargo Securities and BofA Merrill Lynch are the joint bookrunners on the deal.
NephroGenex (NRX), a clinical-stage biotech developing treatments for kidney disease, plans to raise $40 million by offering 3.1 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, NephroGenex would command a market value of $115 million. NephroGenex, which was founded in 2004, booked $0 million in sales over the last 12 months. The Research Triangle Park, NC-based company plans to list on the NASDAQ under the symbol NRX. Aegis Capital is the lead bookrunner on the deal.
Revance Therapeutics (RVNC), a clinical-stage biotech developing enhanced formulations of botulinum toxin, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Revance Therapeutics would command a market value of $253 million. Revance Therapeutics, which was founded in 1999, booked $0 million in sales over the last 12 months. The Newark, CA-based company plans to list on the NASDAQ under the symbol RVNC. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal.
uniQure (QURE), a biotech developing gene therapies for the treatment of orphan diseases, plans to raise $64 million by offering 4.6 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, uniQure would command a market value of $235 million. uniQure, which was founded in 1998, booked $3 million in sales over the last 12 months. The Amsterdam, Netherlands-based company plans to list on the NASDAQ under the symbol QURE. Jefferies & Co., Leerink Partners and Piper Jaffray are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 9 IPO pricings. Dicerna Pharmaceuticals (DRNA), which is developing RNAi therapeutics for the treatment of rare liver disease and cancer, was the week's winner, ending up 174% from its IPO price.
